Non-Cystic Fibrosis Bronchiectasis (NCFB) Market

The non-cystic fibrosis bronchiectasis (NCFB) market has been comprehensively analyzed in IMARC's new report titled "Non-Cystic Fibrosis Bronchiectasis (NCFB) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Non-cystic fibrosis bronchiectasis (NCFB) is a chronic respiratory condition characterized by irreversible dilation and damage to the bronchi, the airways that carry air to the lungs. Unlike cystic fibrosis-related bronchiectasis, NCFB is not associated with a genetic disorder. Symptoms of NCFB include chronic cough, excessive sputum production, recurrent respiratory infections, and shortness of breath. These manifestations arise from the weakened and widened bronchial tubes, leading to impaired mucus clearance and increased susceptibility to bacterial infections. Diagnosing NCFB involves a thorough clinical evaluation, including a detailed medical history, physical examination, and imaging studies such as high-resolution computed tomography (HRCT) scans. The imaging helps to identify bronchial dilation and airway abnormalities. Additionally, pulmonary function tests may also be conducted to assess lung function and airflow limitation.

The escalating incidence of bronchioles damage, leading to chronic inflammation and recurrent respiratory infections, is primarily driving the non-cystic fibrosis bronchiectasis (NCFB) market. In addition to this, the inflating utilization of effective medications, including mucolytics, bronchodilators, antibiotics, etc., to treat the ailment, is also creating a positive outlook for the market. These pharmaceutical interventions aim at managing symptoms and preventing further exacerbations, thereby improving the quality of life for patients. Moreover, the widespread adoption of comprehensive respiratory therapies, such as airway clearance techniques and pulmonary rehabilitation, which can mitigate the impact of NCFB, is bolstering the market growth. Apart from this, the rising usage of pulsed dye laser techniques, targeting aberrant blood vessels and gaining prominence for selective destruction and lightening of affected bronchial areas is acting as another significant growth-inducing factor. Additionally, the emerging popularity of pulmonary rehabilitation, which includes a comprehensive program involving exercise, education, and support to improve overall lung function and reduce symptoms, is expected to drive the non-cystic fibrosis bronchiectasis (NCFB) market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the non-cystic fibrosis bronchiectasis (NCFB) market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for non-cystic fibrosis bronchiectasis (NCFB) and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the non-cystic fibrosis bronchiectasis (NCFB) market in any manner.

Recent Developments:

• In July 2024, Armata Pharmaceuticals stated that it had completed enrollment in its Tailwind Phase 2 clinical trial of inhaled AP-PA02 in patients with NCFB and chronic pulmonary Pseudomonas aeruginosa (P. aeruginosa) infection.
• In May 2024, Insmed Incorporated reported encouraging topline results from the ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 trial to evaluate brensocatib's effectiveness, safety, and tolerability in patients with non-cystic fibrosis bronchiectasis. The study accomplished its primary aim, with both brensocatib dose strengths showing statistically significant reductions in the annualized rate of pulmonary exacerbations (PEs) compared to placebo. The study also met several of its predetermined secondary goals with statistical significance.
• In April 2024, Renovion Inc. reported the topline results of the Phase 2 CLIMB study of ARINA-1 in people with non-cystic fibrosis bronchiectasis. Analysis of sputum samples from the ARINA-1 treatment arm indicated a decrease in mucus viscosity and neutrophil elastase relative to placebo, validating ARINA-1's previously documented mechanism of action data and providing strong mechanical support for the benefits in quality of life.

Key Highlights:

• The prevalence of NCFB in the general population is estimated to be 39.9 cases per 100,000 people.
• There are around 500,000 people living with NCFB in the United States currently.
• In the U.S., more women than males are diagnosed with NCFB.
• In the United States, NCFB is more common in patients of Asian ethnicity.
• The frequency of NCFB increases with age, peaking around the ages of 80 and 84.

Drugs:

Brensocatib is a small molecule, oral, reversible dipeptidyl peptidase 1 (DPP1) inhibitor that Insmed is developing for the treatment of bronchiectasis. DPP1 is an enzyme that activates neutrophil serine proteases (NSPs), including neutrophil elastase, when they develop in the bone marrow.

CHF 6333 is being developed for the treatment of respiratory illnesses including non-cystic fibrosis bronchiectasis and cystic fibrosis. It is designed as a 24-hour dry powder inhaler (DPI) formulation. It works by targeting neutrophil elastase. The drug candidate is a new chemical entity (NCE).

ARINA-1 is a novel at-home nebulized medication that improves lung health by removing mucus, lowering inflammation, and limiting bacterial growth. ARINA-1 may greatly enhance the quality of life and long-term results of persons with NCFB by thinning mucus and allowing it to be cleared from the lungs while also functioning as a potent anti-inflammatory drug in the airway.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the non-cystic fibrosis bronchiectasis (NCFB) market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the non-cystic fibrosis bronchiectasis (NCFB) market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape

This report also provides a detailed analysis of the current non-cystic fibrosis bronchiectasis (NCFB) marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report

Key Questions Answered in this Report

Market Insights

• How has the non-cystic fibrosis bronchiectasis (NCFB) market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the non-cystic fibrosis bronchiectasis (NCFB) market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the non-cystic fibrosis bronchiectasis (NCFB) market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of non-cystic fibrosis bronchiectasis (NCFB) across the seven major markets?
• What is the number of prevalent cases (2018-2034) of non-cystic fibrosis bronchiectasis (NCFB) by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of non-cystic fibrosis bronchiectasis (NCFB) by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with non-cystic fibrosis bronchiectasis (NCFB) across the seven major markets?
• What is the size of the non-cystic fibrosis bronchiectasis (NCFB) patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of non-cystic fibrosis bronchiectasis (NCFB)?
• What will be the growth rate of patients across the seven major markets?
   

Non-Cystic Fibrosis Bronchiectasis (NCFB): Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for non-cystic fibrosis bronchiectasis (NCFB) drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the non-cystic fibrosis bronchiectasis (NCFB) market?
• What are the key regulatory events related to the non-cystic fibrosis bronchiectasis (NCFB) market?
• What is the structure of clinical trial landscape by status related to the non-cystic fibrosis bronchiectasis (NCFB) market?
• What is the structure of clinical trial landscape by phase related to the non-cystic fibrosis bronchiectasis (NCFB) market?
• What is the structure of clinical trial landscape by route of administration related to the non-cystic fibrosis bronchiectasis (NCFB) market?